secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2026-08-06T20:06:04+00:00
Accession:  0001048477-26-000015
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin Q2 revenue up 20% to $990M; GAAP EPS $0.23 vs $1.23; raises VOXZOGO guidance
--------------------------------------------------------------------------------

- Total revenues $990M (+20% YoY); GAAP net income $45M ($0.23 diluted EPS) vs $241M ($1.23) in Q2 2025.
- Non-GAAP income $236M ($1.20 diluted EPS) vs $282M ($1.44) in prior year, down 16%.
- VOXZOGO revenue $253M (+14% YoY); full-year guidance raised to at least $1B.
- Amicus acquisition closed April 27; cost synergies of ~$280M GAAP / ~$220M non-GAAP expected fully realized by 2028.
- Pipeline: sNDA submitted for VOXZOGO in hypochondroplasia; BMN 401 discontinued after Phase 3 miss.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/0001048477-26-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/bmrn-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001048477-26-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer